Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | SELL | P14151 | 1/20 | 0.37 |
| ▸ | SELP | P16109 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 3/20 | 0.36 |
| ▸ | CA1 | P00915 | 3/20 | 0.36 |
| ▸ | CA2 | P00918 | 3/20 | 0.36 |
| ▸ | CA7 | P43166 | 3/20 | 0.36 |
| ▸ | CA9 | Q16790 | 3/20 | 0.36 |
| ▸ | CA4 | P22748 | 2/20 | 0.36 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.36 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.36 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.36 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.36 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.36 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27875807 | 0.95 | CYP1A2 (0.48) | CYP1A2ALDH1A1ALOX15THRBKDM4E | |
| SCHEMBL8880150 | 0.93 | CYP1A2 (0.46) | CYP1A2ALDH1A1ALOX15KDM4ESELL | |
| SCHEMBL1665864 | 0.85 | THRB (0.48) | CYP1A2ALDH1A1ALOX15THRBKDM4E | |
| SCHEMBL27554808 | 0.83 | HAAO (0.41) | CYP1A2ALDH1A1ALOX15THRBKDM4E | |
| SCHEMBL1988762 | 0.83 | CYP1A2 (0.61) | CYP1A2ALDH1A1ALOX15KDM4ESELL | |
| SCHEMBL29445717 | 0.83 | CYP1A2 (0.61) | CYP1A2ALDH1A1ALOX15KDM4ESELL | |
| SCHEMBL22989 | 0.83 | CYP1A2 (0.61) | CYP1A2ALDH1A1ALOX15KDM4ESELL | |
| SCHEMBL2953498 | 0.82 | ALDH1A1 (0.50) | ALDH1A1ALOX15THRBKDM4ECA12 | |
| SCHEMBL411156 | 0.82 | ALDH1A1 (0.50) | ALDH1A1ALOX15THRBKDM4ECA12 | |
| SCHEMBL25342214 | 0.80 | SELL (0.45) | CYP1A2ALDH1A1ALOX15KDM4ESELL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5472710-A | Pharmaceutical preparation to be administered orally with controlled release of active substance and method for its manufacture | SCHWARZ PHARMA AG (DE) | 1995-12-05 | — | — | US | claimed |
| EP-0338383-B1 | PHARMACEUTICAL PREPARATION TO BE ADMINISTERED ORALLY WITH CONTROLLED RELEASE OF ACTIVE SUBSTANCE AND METHOD FOR ITS MANUFACTURE | SCHWARZ PHARMA AG (DE) | 1993-03-24 | — | — | EP | claimed |
| CN-101903016-A | Bupropion hydrobromide and therapeutic uses | BIOVAIL LAB INT SRL | 2010-12-01 | — | — | CN | disclosed |
| US-20090041843-A1 | PHARMACEUTICAL PREPARATION HAVING EXCELLENT PHOTOSTABILITY | KOWA CO., LTD. (JP) | 2009-02-12 | — | — | US | disclosed |
| EP-1944029-A1 | PHARMACEUTICAL PREPARATION HAVING EXCELLENT PHOTOSTABILITY | Kowa Company, Ltd. (JP) | 2008-07-16 | — | — | EP | disclosed |
| EP-0917575-A1 | USE OF A LESTR/FUSIN/CXCR4 RECEPTOR LIGAND CHEMOKINE (SDF-1) FOR TREATING OR PREVENTING HIV-TYPE VIRAL INFECTION | INSTITUT PASTEUR (FR) | 1999-05-26 | — | — | EP | disclosed |
| WO-1998006751-A9 | MCP-3, RANTES AND MIP-1ALPHA RECEPTOR ANTAGONISTS | — | 1998-04-30 | — | — | WO | disclosed |
| WO-1998006751-A1 | MCP-3, RANTES AND MIP-1ALPHA RECEPTOR ANTAGONISTS | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1998-02-19 | — | — | WO | disclosed |
| WO-1998004698-A1 | USE OF A LESTR/FUSIN/CXCR4 RECEPTOR LIGAND CHEMOKINE (SDF-1) FOR TREATING OR PREVENTING HIV-TYPE VIRAL INFECTION | INSTITUT PASTEUR (FR) | 1998-02-05 | — | — | WO | disclosed |
| US-5472710-A | Pharmaceutical preparation to be administered orally with controlled release of active substance and method for its manufacture | SCHWARZ PHARMA AG (DE) | 1995-12-05 | — | — | US | disclosed |
| EP-0302987-B1 | COMPOSITIONS FOR THE PREPARATION OF INTUMESCENT MOULDINGS AND SEMI-FINISHED PRODUCTS, AND THEIR USE IN ARCHITECTURAL FIREPROOFING | Dr. Wolman GmbH (DE) | 1992-07-15 | — | — | EP | disclosed |
| EP-0302987-A1 | Compositions for the preparation of intumescent mouldings and semi-finished products, and their use in architectural fireproofing | Dr. Wolman GmbH (DE) | 1989-02-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090041843-A1 | PHARMACEUTICAL PREPARATION HAVING EXCELLENT PHOTOSTABILITY | HMGCR, PCSK9, CYP4A11 | CYP1A2 663/4885ALDH1A1 3431/4885ALOX15 3055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.